CancerVax Corp.

Dr. Lakey has been recognized nationally and internationally for his groundbreaking research in cell and tissue transplantation for patients suffering from diabetes and cancerLEHI, Utah, July 26, 2023 (GLOBE NEWSWIRE) -- CancerVAX, developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, reported that the Company has appointed Dr. Jonathan Lakey to CancerVAX’s Board of Advisors. Dr. Lakey graduated from the University of Alberta with a BS, MS and PhD and received post-doctoral training in Indianapolis and Seattle. Dr. Lakey is currently the Professor of Surgery and Biomedical Engineering and the Director of the Clinical Islet Program at University of California Irvine. Prior to that, he was the Director of the Comprehensive Tissue Bank at the University of Albert. Dr. Lakey is most well-known for co-inventing the “Edmonton Protocol”, along with Dr. James Shapiro, which aided in the improvement of islet isolation techniques for patients with Type 1 diabetes, a recognized major advancement in the treatment of diabetes. The Edmonton Protocol allows patients to receive islet transplants from the enzymes of cadavers and has had a success rate of over 75%. This development has informed treatments for diabetic patients, but has also opened the door for similar treatments for patients with cancer who have compromised organs from the disease or from chemotherapy and radiation. Dr. Lakey has done extensive research in the fields of oncology, stem cells and organ transplantation. He is the recipient of the Outstanding Leadership in Science Award from Alberta Science & Technology, Outstanding Achievement Award from the Canadian Diabetes Association, Awards from the Royal College of Physicians and Surgeons and was honored with the Meritorious Service Medal (2005) by the Governor-General of Canada. Dr. Lakey has published over 495 scientific papers, 45 book chapters, submitted over 500 scientific abstracts and published a book on islet isolation. CancerVAX CEO Ryan Davies said, “We are honored to have Dr. Lakey join our Board of Advisors. His decades of experience will help us better understand new ideas in oncology immunotherapy as we work on developing new cancer drugs”. “I’m excited to be working with Ryan and the CancerVAX team. This is a noble cause and I am honored to have a part in the exciting work CancerVAX is doing”, said Dr. Lakey. Dr. Lakey recently appeared on the CancerVAX CEO Podcast and the video can be viewed at https://www.youtube.com/watch?v=kS54nCFPPVM For more information about CancerVAX, please visit http://www.cancervax.com/. About Us CancerVAX, Inc. is a pre-clinical biotechnology company developing a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer. Working with a team of experienced cancer researchers and physicians at UCLA, we intend to create a Universal Cancer Vaccine that will detect, mark, and destroy only the diseased cells with an incredibly high level of precision. Much like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, our cancer vaccine will leverage the body’s own immune system to destroy cancer cells. As we develop our universal cancer vaccine, we are also working with UCLA to develop single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. We look forward to the day when treating cancer will be as simple as getting a flu shot. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Press Contact:CancerVAX, Inc.Tel: (805) 356-1810info@CancerVAX.com

Three separate teams of physician scientists at UCLA working on three different parts of the project have made significant progress and are ready to merge their work into a complete proof-of-concept vaccine constructLEHI, Utah, June 27, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today reports that after nearly a year of research, the UCLA team is ready to begin integrating their combined work into a complete vaccine construct for next phase testing and optimization. In mid-2022, CancerVAX entered into a Sponsored Research Agreement with UCLA to develop a universal cancer vaccine (“UCV”) that can precisely detect, mark and kill cancer cells, while leaving healthy cells intact. This novel approach is comprised of three distinct parts: DETECT – Dr. Christopher Seet is leading a research program to overcome the shortcomings of existing cancer vaccines that target a single natural tumor marker (i.e. neoantigen), by using multiple signals for detecting cancer cells to enable high precision targeting. Dr. Seet’s team has completed their in-vitro experiments and has selected two candidate strategies for incorporating into a complete universal cancer vaccine profile. MARK – Dr. Satiro De Oliveira is leading a research program to create the recipe and genetic instructions to force cancer cells to do one of three things: (1) attract more of the body’s natural immune cells to the cancer cell, like “bees to honey”; (2) force cancer cells express markers that look like known diseases, such as COVID or tetanus, so existing immunizations can be used to kill cancer cells; or (3) express a completely novel non-natural biomarker allowing modern vaccine technologies to easily target them. Dr. Oliveira’s team has candidate strategies for all three approaches to be incorporated into a complete universal cancer vaccine construct. KILL – Dr. Steven Jonas is leading a team to develop an advanced lipid nanoparticle that contains all the “DETECT” and “MARK” mechanisms to enable the killing of cancer cells. Dr. Jonas’s team has completed numerous experiments and has selected one strong lipid nanoparticle candidate for integrating the various pieces into a complete prototype vaccine that can be injected for in-vivo mouse studies and optimization. Byron Elton, Chief Marketing Officer of CancerVAX, described the UCV in simple terms, “Our UCV is not a pharmaceutical chemical compound. It is a next generation immune based vaccine technology that we believe can be programmed to hunt down cancer cells, uniquely mark and kill them. This concept is inspired by the recent clinical successes of single disease cancer vaccines, such as those being developed by Pfizer and Moderna. More importantly, it was inspired by the global success of the COVID vaccine, which was developed in record time, manufactured at record low costs, and distributed at record scale, and restarted a halted global economy, all within 2 years. The COVID vaccine relied heavily on lipid nanoparticle and messenger RNA (mRNA) technology, both of which we are leveraging in the development of our universal cancer vaccine.” Ryan Davies, CEO of CancerVAX commented, “According to the World Health Organization, 13.9 billion COVID vaccines were administered globally. The CDC reports that over 81% of Americans have received the COVID vaccine. This clearly demonstrates the efficiency of lipid nanoparticles and immune-based strategies to fight diseases. This is an extraordinary development. We feel so privileged to be working with UCLA, one of the top cancer research and treatment institutions in the world, to develop our novel cancer vaccine.” For more information about CancerVAX, please visit http://www.cancervax.com/. About Us CancerVAX, Inc. is a pre-clinical biotechnology company developing a breakthrough universal cancer vaccine to fight cancer using the body’s immune system. Working with a team of experienced cancer researchers and physicians at UCLA, we intend to create a Universal Cancer Vaccine that will detect, mark, and destroy only the diseased cells with incredible precision. Like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, our cancer vaccine will leverage the body’s immune system to destroy cancer cells. As we develop our universal cancer vaccine, we work with UCLA to develop single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults. We look forward to the day when treating cancer will be as simple as getting a flu shot. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise. Press Contact:CancerVAX, Inc.Tel: (805) 356-1810communications@CancerVAX.com

Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments LEHI, Utah, June 14, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that it recently launched a funding round of up to $10 million. Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments. CancerVax CEO, Ryan Davies said, “We’re working with a research team at UCLA to help us develop these treatments. We’ve raised $2 million of seed funding thus far and are using the StartEngine platform to raise an additional $10 million to further the development of these novel cancer therapies.” The offering is available to the general public on StartEngine, one of the biggest online platforms in the country. For more information about the offering, please visit For more information about CancerVax, please visit . _________________________ This Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. You should read the Offering Circular and Risks related to this offering before investing. About Us CancerVAX, Inc. is a pre-clinical biotechnology company developing a breakthrough universal cancer vaccine to fight cancer using the body’s immune system. Working with a team of experienced cancer researchers and physicians at UCLA, we intend to create a Universal Cancer Vaccine that will detect, mark, and destroy only the diseased cells with incredible precision. Like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, our cancer vaccine will leverage the body’s immune system to destroy cancer cells. As we develop our universal cancer vaccine, we work with UCLA to develop single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults. We look forward to the day when treating cancer will be as simple as getting a flu shot. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise. Press Contact: CancerVAX, Inc. Tel: (805) 356-1810 communications@CancerVAX.com